Human Umbilical Cord Mesenchymal Stromal Cell Transplantation in Myocardial Ischemia (HUC-HEART Trial). A Study Protocol of a Phase 1/2, Controlled and Randomized Trial in Combination with Coronary Artery Bypass Grafting
- 689 Downloads
Mesenchymal stem cells (MSCs), which may be obtained from the bone marrow, have been studied for more than a decade in the setting of coronary artery disease (CAD). Adipose tissue-derived MSCs have recently come into focus and are being tested in a series of clinical trials. MSC-like cells have also been derived from a variety of sources, including umbilical cord stroma, or HUC-MSCs. The HUC-HEART trail (ClinicalTrials.gov Identifier: NCT02323477) is a phase 1/2, controlled, multicenter, randomized clinical study of the intramyocardial delivery of allogeneic HUC-MSCs in patients with chronic ischemic cardiomyopathy. A total of 79 patients (ages 30–80) with left ventricle ejection fractions ranging between 25 and 45 % will be randomized in a 2:1:1 pattern in order to receive an intramyocardial injection of either HUC-MSCs or autologous bone marrow-derived mononuclear cells (BM-MNCs) in combination with coronary arterial bypass grafting (CABG) surgery. The control group of patients will receive no cells and undergo CABG alone. Human HUC-MSCs will be isolated, propagated and banked in accordance with a cGMP protocol, whereas the autologous BM-MNCs will be isolated via aspiration from the iliac crest and subsequently process in a closed-circuit cell purification system shortly before cell transplantation. The cell injections will be implemented in 10 peri-infarct areas. Baseline and post-transplantation outcome measures will be primarily utilized to test both the safety and the efficacy of the administered cells for up to 12 months.
KeywordsUmbilical cord MSC Bone marrow MNC Ischemic cardiomyopathy Regenerative medicine Stem cell therapy Clinical trial
This project was supported by SANTEZ, Project # 0741-STZ-2014 (AC, ATU, OC) and the ATIGEN-CELL Technologies Cell and Gene Center (ME).
Conflict of Interest
One of the authors (ME) works as a scientist for stem cell manufacturing at an ATIGEN-CELL cell production facility. The remaining authors have no conflicts of interest to declare regarding the publication of this manuscript.
- 5.Fisher, S.A., Brunskill, S.J., Doree, C., Mathur, A., Taggart, D.P., & Martin-Rendon, E. (2014). Stem cell therapy for chronic ischaemic heart disease and congestive heart failure. The Cochrane Collaboration., John Wiley & Sons, Ltd.Google Scholar
- 13.Li, X., Hu, Y.D., Guo, Y., et al. (2014). Safety and Efficacy of Intracoronary Human Umbilical Cord-Derived Mesenchymal Stem Cell Treatment for Very Old Patients with Coronary Chronic Total Occlusion. Curr Pharm Des.Google Scholar
- 29.Sorrentino, S. A., Bahlmann, F. H., Besler, C., et al. (2007). Oxidant stress impairs in vivo reendothelialization capacity of endothelial progenitor cells from patients with type 2 diabetes mellitus: restoration by the peroxisome proliferator-activated receptor-gamma agonist rosiglitazone. Circulation, 116, 163–73.CrossRefPubMedGoogle Scholar
- 30.Assmus, B., Fischer-Rasokat, U., Honold, J., et al. (2007). Transcoronary transplantation of functionally competent BMCs is associated with a decrease in natriuretic peptide serum levels and improved survival of patients with chronic postinfarction heart failure: results of the TOPCARE-CHD Registry. Circulation Research, 100, 1234–41.CrossRefPubMedGoogle Scholar
- 33.(2013). European Pharmacopoeia. European Directorate for the Quality of Medicines & HealthCare (EDQM). Strasbourg, France.Google Scholar
- 39.Hare, J. M., Traverse, J. H., Henry, T. D., et al. (2009). A randomized, double-blind, placebo-controlled, dose-escalation study of intravenous adult human mesenchymal stem cells (prochymal) after acute myocardial infarction. Journal of the American College of Cardiology, 54, 2277–86.PubMedCentralCrossRefPubMedGoogle Scholar
- 40.Houtgraaf, J. H., den Dekker, W. K., van Dalen, B. M., et al. (2012). First experience in humans using adipose tissue-derived regenerative cells in the treatment of patients with ST-segment elevation myocardial infarction. Journal of the American College of Cardiology, 59, 539–40.CrossRefPubMedGoogle Scholar
- 50.Pereira, W. C., Khushnooma, I., Madkaikar, M., & Ghosh, K. (2008). Reproducible methodology for the isolation of mesenchymal stem cells from human umbilical cord and its potential for cardiomyocyte generation. Journal of Tissue Engineering and Regenerative Medicine, 2, 394–9.CrossRefPubMedGoogle Scholar
- 54.Anzalone, R., Corrao, S., Lo Iacono, M., et al. (2013). Isolation and characterization of CD276+/HLA-E+ human subendocardial mesenchymal stem cells from chronic heart failure patients: analysis of differentiative potential and immunomodulatory markers expression. Stem Cells and Development, 22, 1–17.CrossRefPubMedGoogle Scholar
- 55.Lopez, Y., Lutjemeier, B., Seshareddy, K., et al. (2013). Wharton’s jelly or bone marrow mesenchymal stromal cells improve cardiac function following myocardial infarction for more than 32 weeks in a rat model: a preliminary report. Current Stem Cell Research & Therapy, 8, 46–59.CrossRefGoogle Scholar
- 56.Santos Nascimento, D., Mosqueira, D., Sousa, L. M., et al. (2014). Human umbilical cord tissue-derived mesenchymal stromal cells attenuate remodeling after myocardial infarction by proangiogenic, antiapoptotic, and endogenous cell-activation mechanisms. Stem Cell Research & Therapy, 5, 5.CrossRefGoogle Scholar